Insilico Medicine and Eli Lilly to Anchor 13th Aging Research & Drug Discovery (ARDD) Meeting at the David Rubenstein Treehouse at Harvard University
Organized by Insilico Medicine, the world’s largest longevity biotechnology conference kicks off Boston Longevity Week this October with top-tier global pharmaceutical support.
BOSTON, MA — July 10, 2026 — The 13th Aging Research & Drug Discovery (ARDD) Meeting, the world’s largest conference dedicated to longevity biotechnology, will take place from October 1-3, 2026, at the David Rubenstein Treehouse at Harvard University. Marking the high-profile launch of Boston Longevity Week, this landmark event is officially organized by Insilico Medicine, which also anchors the conference as a Tier 1 sponsor alongside Eli Lilly.
As longevity science rapidly transitions from theoretical concepts to multi-billion-dollar therapeutic pipelines, ARDD 2026 stands as the premier global nexus connecting basic science, clinical research, big pharma, and institutional investors. Moving the conference to Boston—the global epicenter of biomedical innovation—reflects the field's evolution into mainstream medicine.
Building on the massive momentum of previous years—including ARDD 2025 in Copenhagen, where leadership from Eli Lilly and Novo Nordisk discussed the profound longevity potential of GLP-1 receptor agonists in Nature Biotechnology—the 2026 conference solidifies aging research as a core pillar of healthcare. Top-tier pharmaceutical companies are now actively developing commercial programs targeting fibrosis, immunology, CNS, cardiometabolic diseases, anti-muscle wasting, and cellular rejuvenation.
The comprehensive 2026 program features highly specialized daily tracks designed to drive clinical translation and industry growth:
October 1: Clinical Development Day and the Longevity Medicine Track
October 2: AI in Drug Discovery Track
October 3: Future Technology Track
In addition to the main scientific program, the conference will host multiple high-profile, invite-only receptions to facilitate networking among global decision-makers. Confirmed speakers already include executive leaders from 10 of the world's top pharmaceutical companies.
The conference is steered by an elite panel of global chairs representing top academic and scientific institutions: Vadim Gladyshev and Jesse Poganik (Harvard Medical School); Alex Zhavoronkov (Insilico Medicine); Morten Scheibye-Knudsen and Daniela Bakula (The University of Copenhagen); Evelyne Bischof (Sheba Longevity Center); and Maximilian Unfried (National University of Singapore). Further cementing the meeting’s influence on global health economics, the McKinsey Health Institute joins ARDD 2026 as the Sole Knowledge Partner.
Reflecting its global scale, ARDD 2026 has secured backing from an array of prominent biotechnology and financial institutions. Joining Tier 1 partners Eli Lilly and Insilico Medicine are Tier 3 sponsors AbbVie, BioAge, Human Longevity, Tally Health, Maxwell Biosciences, Gordian, TruDiagnostic, and Cyclarity Therapeutics. Synaro Capital supports the event as a Tier 4 sponsor, alongside Tier 5 sponsors including Morgan Stanley, Healthy Longevity, Intrinsic Capacity, and QuadraScope.
To secure early-bird pricing and receive immediate notification when the registration system goes live, prospective attendees are encouraged to join the priority waitlist. Please visit the official registration portal at https://agingpharma.org/registration or learn more at agingpharma.org.
Sponsorship opportunities remain available across multiple tiers, including customized packages for industry partners looking to interface with decision-makers from venture capital, academia, and big pharma.
Media & Sponsorship Inquiries
For press credentials, interview requests with the conference chairs, or remaining sponsorship inquiries, please contact:
General Inquiries: ardd@pharma.ai
Sponsorship Coordination: pogan@bwh.harvard.edu
Media Attendance: andrew@insilicomedicine.com
Updates & Social Media: Follow X @ARDD_Meeting or visit agingpharma.org
About the Aging Research & Drug Discovery (ARDD) Meeting The ARDD Meeting is the world’s largest and most influential conference focused on aging and longevity biotechnology. ARDD brings together academia, clinicians, industry leaders, and institutional investors to translate the latest breakthroughs in aging science into practical R&D and tangible therapeutic programs.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma. AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.
For more information, please visit www.insilico.com
As an AI-native biotechnology company, Insilico is redefining the efficiency of preclinical drug development through its advanced AI and automation platform, setting a new standard for the industry. While traditional early-stage drug discovery typically takes 2.5 to 4 years, Insilico has consistently reached preclinical candidate (PCC) nomination in an average of just 12 to 18 months, with only 60 to 200 molecules synthesized and tested per program. Since 2021, the company has nominated 31 PCCs, 13 of which have received IND approval or clearance.
While expanding the practical applications of its technology in drug discovery and life science research, Insilico is also continuously enhancing the performance of its AI platform. Drawing on extensive experience and datasets from its training platform, the company has distilled thousands of benchmarks and integrated them into MMAI Gym. Serving as both a “trainer and benchmark” for scientific AI, MMAI Gym enables organizations to train models for domain-specific reasoning while rigorously evaluating their performance on real-world tasks, advancing the path toward pharma superintelligence. To date, Human Longevity and Liquid AI have collaborated with Insilico, joining as partners of MMAI Gym.